V12 SENTINEL ENGINE · AI MARKET ANALYSIS
Mid
S
SNDXAI Stock Diagnostic Report

Syndax plummets as IPF asset axatilimab fails in phase 2 trial

Syndax's IPF treatment axatilimab failed in a Phase 2 trial, causing its stock price to plummet.

View Source Article ↗
AI CATALYST SCORE50 / 100Score computed by Sentinel V12
REFERENCE PRICENot measuredReference entry price at analysis time
+
ANALYSIS HISTORY

SNDX Analysis History (Last 30 Days)

Diagnosed AtTickerAI ScoreTier
2026-10-12 20:42:18SNDX50MidView Report →
2026-10-12 11:54:45SNDX60MidView Report →
2026-08-05 06:36:47SNDX88S-ClassView Report →
View Full History for SNDX (Blueprint) →